Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis

por Maher, Toby M., Schlecker, Christina, Luedtke, Doreen, Bossert, Sebastian, Zoz, Donald F., Schultz, Armin
Publicado 2022

Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study

por Assassi, Shervin, Shao, Nan, Yin, Ziwei, Volkmann, Elizabeth R., Zoz, Donald F., Leonard, Thomas B.
Publicado 2022

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis

por Richeldi, Luca, Azuma, Arata, Cottin, Vincent, Hesslinger, Christian, Stowasser, Susanne, Valenzuela, Claudia, Wijsenbeek, Marlies S, Zoz, Donald F, Voss, Florian, Maher, Toby M
Publicado 2022

Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations

por Jones, Steve, Flewett, Maxine, Flewett, Ron, Lee, Sharon, Vick, Bill, Thompson, Milla, Pinnetti, Sabine, Zoz, Donald F., Hoffmann-Vold, Anna-Maria, Kreuter, Michael, Maher, Toby M.
Publicado 2023

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)

por Richeldi, Luca, Azuma, Arata, Cottin, Vincent, Kreuter, Michael, Maher, Toby M, Martinez, Fernando J, Oldham, Justin M, Valenzuela, Claudia, Gordat, Maud, Liu, Yi, Stowasser, Susanne, Zoz, Donald F, Wijsenbeek, Marlies S
Publicado 2023